Adenosine Therapy in Arrhythmias
Introduction to Adenosine Therapy
- The American Heart Association recommends adenosine as the first-line pharmacological agent for terminating AV nodal re-entrant tachycardia (AVNRT) and AV re-entrant tachycardia (AVRT), with success rates of 78-96% and specifically 95% for AVNRT 1, 2
- Adenosine works by selectively blocking AV nodal conduction through A1 receptor activation, which produces negative chronotropic and dromotropic effects 2
Administration and Dosage
- The initial dose of adenosine for terminating supraventricular tachycardia is 6 mg IV push via large proximal vein, followed immediately by 20 mL saline flush 1
- If no conversion within 1-2 minutes, administer 12 mg IV push, and if still no response, one additional 12 mg dose may be given 1
- The entire effect of adenosine occurs within 30 seconds of administration due to its extremely short half-life of less than 10 seconds 3
Diagnostic Applications
- Adenosine can unmask atrial flutter or atrial tachycardia by temporarily slowing AV conduction, allowing visualization of flutter waves or P waves on ECG 1, 2
- In patients with wide-complex tachycardia of uncertain etiology, adenosine helps differentiate SVT with aberrancy from VT 2, 3
Safety Considerations
- Absolute contraindications for adenosine include asthma or bronchospastic lung disease, and second- or third-degree AV block or sick sinus syndrome (unless pacemaker present) 1, 2, 3
- High-risk situations requiring extreme caution include Wolff-Parkinson-White (WPW) syndrome, where adenosine can precipitate atrial fibrillation with rapid ventricular rates via the accessory pathway 1, 3
Special Populations
- Adenosine is safe and effective during pregnancy 1
Post-Conversion Management
- Monitor for immediate recurrence after successful conversion with adenosine, and if recurrence occurs, re-administer adenosine or transition to a longer-acting AV nodal blocking agent 1